Red Yeast Rice for the Treatment of Dyslipidemia

详细信息    查看全文

• 作者：Frances M. Burke (1)
  
  1. Cardiovascular Medicine ; University of Pennsylvania Health System ; 2 East Perelman Center ; 3400 Civic Center Blvd ; Philadelphia ; PA ; 19104 ; USA
  
• 关键词：Red yeast rice ; Monacolin K ; Lovastatin ; Hypercholesterolemia ; Dyslipidemia ; Statin ; associated myalgia (SAM) ; HMG CoA reductase inhibitor ; Xuezhikang ; Mevacor
• 刊名：Current Atherosclerosis Reports
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：17
• 期：4
• 全文大小：205 KB
• 参考文献：1. Gordon, RY, Becker, DJ (2011) The role of red yeast rice for the physician. Curr Atheroscler Rep 13: pp. 73-80 k" title="It opens in new window">CrossRef
  2. Cunningham, E (2011) Is red yeast rice safe and effective for lowering cholesterol?. J Am Diet Assoc 111: pp. 324 k" title="It opens in new window">CrossRef
  3. Musselman, ME, Pettit, RS, Derenski, KL (2012) A review and update of red yeast rice. J Evid Based Complement Alternat Med 17: pp. 33-9 k" title="It opens in new window">CrossRef
  4. Childress, L, Gay, A, Zargar, A, Ito, MK (2013) Review of red yeast rice content and current food and drug administration oversight. J Clin Lipidol 7: pp. 117-22 k" title="It opens in new window">CrossRef
  5. ConsumerLab.com. Red yeast rice supplements review. http://www.consumerlab.com/reviews/Red-Yeast-Rice-Supplements-Review/Red_Yeast_Rice. Accessed November 7, 2014.
  6. Ma, J, Li, Y, Ye, Q, Li, J, Hua, Y, Ju, D (2000) Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem 48: pp. 5220-5 k" title="It opens in new window">CrossRef
  7. Becker, DJ, Gordon, RY, Morris, PB, Yorko, J, Gordon, YJ, Li, M (2008) Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 83: pp. 758-64 k" title="It opens in new window">CrossRef
  8. Heber, D, Yip, I, Ashley, JM, Elashoff, DA, Elashoff, RM, Go, VL (1999) Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr 69: pp. 231-6
  9. Downs, JR, Clearfield, M, Weis, S, Whitney, E, Shapiro, DR, Beere, PA (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: pp. 1615-22 k" title="It opens in new window">CrossRef
  10. Nijjar, P, Burke, F, Bloesch, A, Rader, D (2010) Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 4: pp. 248-58 k" title="It opens in new window">CrossRef
  11. Chen, CH, Jc, Y, Uang, YS, Lin, CJ (2013) Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. Int J Pharm 444: pp. 18-24 k" title="It opens in new window">CrossRef
  12. Lin, CC, Li, TC, Lai, MM (2005) Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemia. Eur J Endocrinol 153: pp. 679-86 k" title="It opens in new window">CrossRef
  13. Verhoeven, V, Lopez Hartmann, M, Remmen, R, Wens, J, Apers, S, Royen, P (2013) Red yeast rice lowers cholesterol in physicians鈥攁 double blind, placebo controlled randomized trial. BMC Complement Altern Med 13: pp. 178-84 k" title="It opens in new window">CrossRef
  14. Moriarty, PM, Roth, EM, Karns, A, Ye, P, Zhao, SP, Liao, Y (2014) Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. J Clin Lipidol 8: pp. 568-75 k" title="It opens in new window">CrossRef
  15. Lu, Z, Kou, W, Du, B, Wu, Y, Zhao, S, Brusco, OA (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101: pp. 1689-93 k" title="It opens in new window">CrossRef
  16. Li, JJ, Lu, ZL, Kou, WR, Chen, Z, Wu, Y, Yu, XH (2009) Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 49: pp. 947-56 k" title="It opens in new window">CrossRef
  17. Li, Y, Jiang, L, Jia, Z, Xin, W, Yang, S, Yang, Q (2014) A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 9: pp. e98611 k" title="It opens in new window">CrossRef
  18. Halbert, SC, French, B, Gordon, RY, Farrar, JT, Schmitz, K, Morris, PB (2010) Tolerability of red yeast rice (2400聽mg twice daily) versus pravastatin (20聽mg twice daily) in patients with previous statin intolerance. Am J Cardiol 105: pp. 198-204 k" title="It opens in new window">CrossRef
  19. Becker, DJ, Gordon, RY, Halbert, SC, French, B, Morris, PB, Rader, DJ (2009) Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150: pp. 830-9 k" title="It opens in new window">CrossRef
  20. Becker, DJ, French, B, Morris, PB, Silvent, E, Gordon, RY (2013) Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial. Am Heart J 166: pp. 187-96 k" title="It opens in new window">CrossRef
  21. Goldberg, AC, Ostlund, RE, Bateman, JH, Schimmoeller, L, McPherson, TB, Spilburg, CA (2006) Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am J Cardiol 97: pp. 376-9 k" title="It opens in new window">CrossRef
  22. Venero, CV, Venero, JV, Wortham, DC, Thompson, PD (2010) Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 105: pp. 664-6 k" title="It opens in new window">CrossRef
  23. Sacks, FM, Pfeffer, MA, Moye, LA, Rouleau, JL, Rutherford, JD, Cole, TG (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: pp. 1001-9 k" title="It opens in new window">CrossRef
  Randomised trial of cholesterol lowering on 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: pp. 1383-9
  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: pp. 1349-57 k" title="It opens in new window">CrossRef
  24. Yang, CW, Mousa, SA (2012) The effect of red yeast rice (Monasucs purpureus) in dyslipidemia and other disorders. Complement Ther Med 20: pp. 466-74 k" title="It opens in new window">CrossRef
  25. National Center for Complementary and Alternative Medicine. http://nccam.nih.gov. Accessed December 5, 2014.
  26. Gordon, RY, Cooperman, T, Obermeyer, W, Becker, DJ (2010) Marked variability of monacolin levels in commercial red yeast rice products: buyer beware!. Arch Intern Med 170: pp. 1722-7
  27. Klimek, M, Wang, S, Ogunkanmi, A (2009) Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P&T A PeerRev J Formul Manag 34: pp. 313-27
  
• 刊物主题：Angiology; Cardiology;
• 出版者：Springer US
• ISSN：1534-6242

文摘

Red yeast rice (RYR) is a Chinese herbal supplement produced by fermenting white rice with the yeast, Monascus purpureus. The Chinese have used RYR to flavor, color, and preserve foods and as a traditional medicine for many years. In the USA, RYR has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia. RYR contains a variety of monacolins, which inhibit hydroxymethylglutaryl-coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. Consumption of RYR has increased recently especially among patients who might be intolerant to standardized therapy due to statin-associated myalgia (SAM). Several clinical trials have shown RYR to be safe, effective, and well tolerated; however, the studies are small and of short duration. The US Food and Drug Administration has prohibited the sale of all RYR products containing monacolin K, which is chemically identical to lovastatin, because it is considered an unapproved drug. However, many RYR supplements continue to remain on the market and lack standardization and quality control.